dalteparin has been researched along with cgp 39393 in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (71.43) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 1 (14.29) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Biemond, BJ; Büller, HR; Levi, M; Nurmohamed, MT; ten Cate, JW | 1 |
Eriksson, BI; Kälebo, P; Magnusson, M; Sivertsson, R | 1 |
Bach, D; Baur, M; Bösch, P; Close, P; Ekman, S; Eriksson, BI; Kälebo, P; Lindbratt, S; Mouret, P; Rosencher, N; Wille-Jørgensen, P | 1 |
Ewenstein, BM | 1 |
Robb, J | 1 |
Bonneau, JC; Drouet, M; Gay, G; Le Sellin, J; Leclere, JM; Nicolie, B | 1 |
Eriksson, BI; Jaffer, AK; Shorr, AF; Smith, J | 1 |
1 review(s) available for dalteparin and cgp 39393
Article | Year |
---|---|
[Delayed hypersensitivity to heparins and heparinoids].
Topics: Aged; Anticoagulants; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug Hypersensitivity; Enoxaparin; Female; Heparin; Heparin, Low-Molecular-Weight; Heparitin Sulfate; Hirudin Therapy; Hirudins; Humans; Hypersensitivity, Delayed; Nadroparin; Recombinant Proteins; Skin Tests | 2002 |
1 trial(s) available for dalteparin and cgp 39393
Article | Year |
---|---|
A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Female; Hirudin Therapy; Hirudins; Humans; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Thrombophlebitis; Treatment Outcome | 1997 |
5 other study(ies) available for dalteparin and cgp 39393
Article | Year |
---|---|
Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Topics: Animals; Blood Coagulation; Drug Synergism; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Infusions, Intravenous; Jugular Veins; Nadroparin; Rabbits; Recombinant Proteins; Thrombin; Thrombosis | 1994 |
Is colour Doppler ultrasound a sensitive screening method in diagnosing deep vein thrombosis after hip surgery?
Topics: Anticoagulants; Dalteparin; Dextrans; Hip Fractures; Hip Prosthesis; Hirudin Therapy; Hirudins; Humans; Incidence; Phlebography; Postoperative Care; Postoperative Complications; Predictive Value of Tests; Recombinant Proteins; Risk; Sensitivity and Specificity; Thrombophlebitis; Ultrasonography, Doppler, Color | 1996 |
Antithrombotic agents and thromboembolic disease.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Humans; Postoperative Complications; Recombinant Proteins; Thrombophlebitis | 1997 |
Recombinant hirudin compared with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Hirudin Therapy; Hirudins; Humans; Postoperative Complications; Recombinant Proteins; Thrombophlebitis | 1998 |
Impact of stage 3B chronic kidney disease on thrombosis and bleeding outcomes after orthopedic surgery in patients treated with desirudin or enoxaparin: insights from a randomized trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Female; Hirudins; Humans; Injections, Subcutaneous; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Patient Selection; Postoperative Hemorrhage; Randomized Controlled Trials as Topic; Recombinant Proteins; Renal Insufficiency, Chronic; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Thrombosis; Time Factors; Treatment Outcome; Young Adult | 2012 |